A Scintigraphy Study in Adults With Diabetic Gastroparesis

CinDome Pharma

Status and phase: Terminated; Phase 2

Conditions: Diabetic Gastroparesis

Treatments: Drug: CIN-102 Dose 2; Drug: Placebo for CIN-102; Drug: CIN-102 Dose 1

Study type: Interventional

Funder types: Industry

Identifiers

NCT04208698

CIN-102-122

Details and patient eligibility

About

This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.

Full description

This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis. The population for this study is adult patients 18 to 70 years old with Type 1 or Type 2 diabetes and a diagnosis of diabetic gastroparesis. The study will consist of two cohorts with approximately 15 subjects in each cohort.

Enrollment: 2 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients 18 to 70 years old, inclusive.
• Type 1 or Type 2 diabetes mellitus, according to American Diabetes Association criteria
• Current diagnosis of diabetic gastroparesis.
• Body Mass Index (BMI) between 18 and 40 kg/m2, inclusive.
• Glycosylated hemoglobin level <11% at Screening.
• Willing to abstain from tobacco or nicotine-containing product use after midnight on the day of the DAS test and throughout the time that gastric emptying is being imaged.
• Willing to abstain from grapefruit, grapefruit products, star fruit, star fruit products, and Seville oranges from 72 hours prior to the Randomization Visit until end of study.

Exclusion criteria

• History of, or current, clinically significant arrhythmias as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, and Torsades de Pointes. Patients with minor forms of ectopy (eg, premature atrial contractions) are not necessarily excluded.
• Clinically significant bradycardia with a resting heart rate under 50 beats per minute, sinus node dysfunction, or heart block.
• Prolonged heart rate-corrected QT interval using Fridericia's formula (QTcF) (QTcF >450 msec for males or QTcF >470 msec for females) based on the average of triplicate ECGs.
• A personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias or family history of sudden death.
• Evidence (based on Screening or Baseline assessments) or history of clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies); surgical conditions; cancer (with the exception of basal or squamous cell carcinoma of the skin and cancer that resolved or has been in remission for >5 years prior to the Screening Visit); or any condition that, in the Investigator's opinion, might significantly interfere with the absorption, distribution, metabolism, or excretion of the study drug.
• History of prolactin-releasing pituitary tumor (ie, prolactinoma).
• Allergic to egg or intolerant to gluten.
• History of alcoholism or drug abuse within 2 years prior to dosing as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition.
• Known or suspected gastric outlet obstruction (eg, peptic stricture) or other gastrointestinal mechanical obstruction.
• Known history or current diagnosis of intestinal malabsorption or pancreatic exocrine disease.
• History or presence of any medical condition or psychiatric disease, which, in the opinion of the Investigator, could interfere with the conduct of the study or would put the patient at unacceptable risk.
• Judged by the Investigator, after reviewing medical and psychiatric history, physical examination, and laboratory evaluation, to be unsuitable for any other reason that may either place the patient at increased risk during participation or interfere with the interpretation of the study outcomes.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Triple Blind

---

2 participants in 4 patient groups, including a placebo group

CIN-102 Tablets Dose 1

Experimental group

Description:

CIN-102 tablets by mouth twice daily for 14 days

Treatment:

Drug: CIN-102 Dose 1

Placebo for CIN-102 Dose 1

Placebo Comparator group

Description:

Placebo tablets by mouth twice daily for 14 days

Treatment:

Drug: Placebo for CIN-102

CIN-102 Dose 2

Experimental group

Description:

CIN-102 tablets by mouth twice daily for 14 days

Treatment:

Drug: CIN-102 Dose 2

Placebo for CIN-102 Dose 2

Placebo Comparator group

Description:

Placebo tablets by mouth twice daily for 14 days

Treatment:

Drug: Placebo for CIN-102